Research from Icahn School of Medicine at Mount Sinai Registers Diabetes Trial
What happened
Paulex Bio Inc. announced the registration of a Phase 1/2a first-in-human trial for PAL-119, an oral small molecule designed to regenerate and restore insulin-producing pancreatic beta cells. The study will evaluate the drug's safety and tolerability in healthy volunteers and adults with Type 1 or Type 2 diabetes. The research originated from the Icahn School of Medicine at Mount Sinai in San Diego.
From prnewswire.com
Why it matters
PAL-119 aims to provide a disease-modifying therapy for both Type 1 and Type 2 diabetes by addressing the loss and dysfunction of beta cells. This approach differs from current diabetes medicines, which typically replace or stimulate insulin production.
From prnewswire.com
Who's involved
- San DiegoLocation where the research originated.
- Icahn School of Medicine at Mount SinaiMedical school where the research was conducted.
- Mount SinaiHamlet within the larger health system.
- Mount Sinai Health SystemHospital network that houses the research unit.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Icahn School of Medicine at Mount SinaiSpeculative
The Icahn School of Medicine at Mount Sinai could see increased funding and prestige from validated research.
- Mount SinaiSpeculative
Mount Sinai might see its funding base strengthened by the success of its academic components.
- Mount Sinai Health SystemSpeculative
Mount Sinai Health System could gain enhanced institutional standing and access to funding.
- National Institutes of HealthSpeculative
National Institutes of Health might see increased attractiveness for future funding.
Keep exploring
The entities involved
-
San Diego
seat of San Diego County, California, United States; second-largest city in California
-
Icahn School of Medicine at Mount Sinai
medical school